Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0IJNAM
|
|||||
---|---|---|---|---|---|---|
ADC Name |
D3-GPC2-PBD
|
|||||
Drug Status |
Investigative
|
|||||
Indication |
In total 2 Indication(s)
Neuroblastoma [ICD11:2A00]
Investigative
Small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
Drug-to-Antibody Ratio |
2.6
|
|||||
Antibody Name |
Fully human D3-GPC2-IgG1
|
Antibody Info | ||||
Antigen Name |
Glypican-2 (GPC2)
|
Antigen Info | ||||
Payload Name |
PBD dimer
|
Payload Info | ||||
Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
Linker Name |
Undisclosed
|
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Standard Type | Value | Units | Animal Model (No. of PDX) |
---|---|---|---|
Tumor Growth Inhibition value (TGI) |
≈ 86.8
|
%
|
COG-N-421x PDX model
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 86.80% (Day 2) | High GPC2 expression (GPC2+++) | ||
Method Description |
Tumors were typically implanted into the flanks of female 5-9 week-old C.B-17 scid mice. Each mouse was then given a single dose of their respective ADC treatments in PBS or vehicle (Day 0) via intraperitoneal (IP) injection. In some efficacy studies, one cohort of mice received 3 subsequent ADC 1 mg/kg IP injections over the following 2 weeks (1 mg/kg x 4 cohort).
Click to Show/Hide
|
||||
In Vivo Model | COG-N-421x PDX model |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.00 pM | High GPC2 expression (GPC2+++) | ||
Method Description |
Cells were incubated with increasing concentrations in tested compounds for 96 h and cell viability was determined by MTS assay.
|
||||
In Vitro Model | Neuroblastoma | SK-N-AS cells | CVCL_1700 | ||
Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 26.60 pM | Positive GPC2 expression (GPC2 +++/++) | ||
Method Description |
Cell lines were plated in 96-well plates (typically between 1,000 and 5,000 cells/well) and treated with serial dilutions of each ADC payload, the D3-GPC2-PBD ADC, or vehicle the following day. After four additional days, cell viability was determined using a CellTiter-Glo Assay.
|
||||
In Vitro Model | Neuroblastoma | NB-SD cells | CVCL_LF68 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.